These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 12083976)

  • 1. Clinical pharmacokinetics and pharmacodynamics of repaglinide.
    Hatorp V
    Clin Pharmacokinet; 2002; 41(7):471-83. PubMed ID: 12083976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
    Owens DR
    Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
    Culy CR; Jarvis B
    Drugs; 2001; 61(11):1625-60. PubMed ID: 11577798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology and clinical experience with repaglinide.
    Massi-Benedetti M; Damsbo P
    Expert Opin Investig Drugs; 2000 Apr; 9(4):885-98. PubMed ID: 11060717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
    Nattrass M; Lauritzen T
    Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S21-31. PubMed ID: 11063281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment.
    Schumacher S; Abbasi I; Weise D; Hatorp V; Sattler K; Sieber J; Hasslacher C
    Eur J Clin Pharmacol; 2001 May; 57(2):147-52. PubMed ID: 11417447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
    Scheen AJ
    Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes.
    Moses R
    Expert Opin Pharmacother; 2000 Dec; 1(7):1455-67. PubMed ID: 11249478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repaglinide: prandial glucose regulation in clinical practice.
    Owens DR; McDougall A
    Diabetes Obes Metab; 2000 Mar; 2 Suppl 1():S43-8. PubMed ID: 11225759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repaglinide--a new compound for the treatment of patients with type 2 diabetes.
    Wolffenbuttel BH
    Neth J Med; 1999 Nov; 55(5):229-34. PubMed ID: 10593133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repaglinide.
    Balfour JA; Faulds D
    Drugs Aging; 1998 Aug; 13(2):173-80. PubMed ID: 9739505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes.
    Strange P; Schwartz SL; Graf RJ; Polvino W; Weston I; Marbury TC; Huang WC; Goldberg RB
    Diabetes Technol Ther; 1999; 1(3):247-56. PubMed ID: 11475269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing.
    van Heiningen PN; Hatorp V; Kramer Nielsen K; Hansen KT; van Lier JJ; De Merbel NC; Oosterhuis B; Jonkman JH
    Eur J Clin Pharmacol; 1999 Sep; 55(7):521-5. PubMed ID: 10501822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repaglinide: a review of its use in type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2012 Jan; 72(2):249-72. PubMed ID: 22268393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.
    Hatorp V; Hansen KT; Thomsen MS
    J Clin Pharmacol; 2003 Jun; 43(6):649-60. PubMed ID: 12817528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.
    Owens DR; Cozma LS; Luzio SD
    Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):19-27. PubMed ID: 12702004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifampin decreases the plasma concentrations and effects of repaglinide.
    Niemi M; Backman JT; Neuvonen M; Neuvonen PJ; Kivistö KT
    Clin Pharmacol Ther; 2000 Nov; 68(5):495-500. PubMed ID: 11103752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose pharmacokinetics of repaglinide in subjects with chronic liver disease.
    Hatorp V; Walther KH; Christensen MS; Haug-Pihale G
    J Clin Pharmacol; 2000 Feb; 40(2):142-52. PubMed ID: 10664920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharma-clinics. Medication of the month. Repaglinide (NovoNorm)].
    Scheen AJ
    Rev Med Liege; 2001 Jun; 56(6):456-9. PubMed ID: 11496727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan.
    Anwar A; Azmi KN; Hamidon BB; Khalid BA
    Med J Malaysia; 2006 Mar; 61(1):28-35. PubMed ID: 16708731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.